These are products that are in the preclinical. Roche may just sit on this or experiment with them. This has been an issue for the company over it's history. Companies licensing stuff and then never moving the projects forward.
Until they license a late stage candidate like the HPV vaccine they won't be legit and I won't feel good as as a shareholder.
I guess I'm a little confused. My understanding is that we would still advance through clinical trials, they would just be footing the bill and looking over our shoulder. If my understanding is correct, then there shouldn't be any issue of Roche doing nothing. If my understanding is wrong, then please correct me.
NO!! They handle the clinical advancement. They pay milestone payments at key points. It they start Phase I trials. They pay us a payment . If they start Phase II another payment and so on but they are not obligated to push anything forward. At any point they can terminate the agreement and stop the progression.
Silly comment. This is a key foundation block. What more could you ask for really? Blue chip. Due diligence underpinning. Takes part of the speculation out of the formula. Now its about execution, dates, and less about bs on the reality of the platform.
NV...I hear a tinge of your disappointment from the ghost of the old GEB/Merck deal. I'm hopeful this may be different. There are posts today putting light on why Merck is in the position they are in. Maybe they are now realizing a squandered opportunity. Competition usually will light a fire under someone's butt. On the other hand if just one of the two indications on licensing gets fast track status - well...it will be major. I agree that they should vpush forward on one vaccine to keep all players and partners on point. Cheers.-it was a good day and a lllooooonnnnggg time coming.
You know EXACTLY what I'm talking about. I hope Roche actually moves this forward. I'm scared that $10 million up front is a drop in the bucket to a company like Roche. They could pay that just to experiment with the technology and never move it forward all the way to market. So frustrating !!